Latest News

Government directs MRRF funds to coronavirus response February 20, 2020

The federal government has announced it will 'fast track $2 million in funding to support Australian research focused on understanding and responding to the coronavirus.

Noxopharm announces alliance to provide compassionate access February 20, 2020

Noxopharm (ASX:NOX) has announced a new clinical alliance with oncology services provider GenesisCare to offer a compassionate access program with its novel lead product candidate, Veyonda.

Immutep provides positive update on immunotherapy trial February 20, 2020

The Sydney-based biotechnology Immutep (ASX:IMM) company has released new positive data from a trial involving its immunotherapy in combination with MSD's KEYTRUDA (pembrolizumab).

Test measures immune response to improve ovarian cancer diagnosis February 18, 2020

Researchers say they have developed a blood test that measures the body’s own immune response to improve diagnosis of ovarian cancer.

EnGeneIC recognised for nanocell platform February 18, 2020

Australian clinical-stage biopharmaceutical company EnGeneIC has been featured in the publication InsightsCare as one of the ten most innovative healthcare nanotech companies to watch.

Companies caught in new compliance regime February 18, 2020

Many Australian-based companies are in the process of coming to terms with a new regulation focussed on slavery.

Researchers combine CRISPR and CAR-T therapies February 18, 2020

The field of personalised medicine is moving quickly but may even be accelerating with researchers now combining new technologies.

Solid half for Cochlear on implant growth February 18, 2020

Cochlear (ASX:COH) has reported a 9 per cent increase in sales revenue for the six months to the end of December 2019 driven by a 14 per cent rise in implant revenue.

CSL jumps again on strong first half February 13, 2020

A significant jump in net profit after tax for CSL in the six months to 31 December 2019 with strong growth in sales of immunoglobulin and flu vaccine.

Starpharma collects milestone payment from AZ February 13, 2020

AstraZeneca has paid a $4.5 million milestone payment to Australian company Starpharma (ASX:SPL) following the successful dosing of the first patient in the phase 1 clinical trial of AZD0466.

Australian company makes progress in small molecule PCSK9 inhibitor February 13, 2020

Australian company Nyrada (ASX:NYR) says it has made major progress in the development of a small molecule PCSK9 inhibitor.

SpeeDx raises additional $15 million in Series B Funding February 13, 2020

SpeeDx, the developer of clinical diagnostics to support patient outcomes, has raised $15 million in additional series B equity investment from US-based Northpond Ventures.

Most Read

New Stories

Aroa Biosurgery launches Myriad in the US

Government directs MRRF funds to coronavirus response

Noxopharm announces alliance to provide compassionate access

Immutep provides positive update on immunotherapy trial

Eureka LIVE: Medtronic Australasia launches new programme at AusMedtech 2020

Test measures immune response to improve ovarian cancer diagnosis

EnGeneIC recognised for nanocell platform

Sign In